Literature DB >> 10493522

Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.

P Fullwood1, S Marchini, J S Rader, A Martinez, D Macartney, M Broggini, C Morelli, G Barbanti-Brodano, E R Maher, F Latif.   

Abstract

Hemizygosity and homozygosity mapping studies show that many common sporadic cancers including lung, breast, kidney, cervical, ovarian, and head and neck cancer display deletions on the short arm of chromosome 3. For ovarian cancer, monochromosomal transfer suppression studies have identified three candidate regions for chromosome 3p ovarian cancer tumor suppressor genes (OCTSGs). To accurately map OCTSG candidate regions, we analyzed 70 ovarian tumors for loss of heterozygosity (LOH) at 20 loci on chromosome 3p that were selected to target those regions proposed to contain tumor suppressor genes for common sporadic cancers. All samples were informative for at least five markers. In 33 (52%) tumors without microsatellite instability, LOH was observed for at least one 3p marker. Analysis of 27 ovarian tumors demonstrating both loss and retention of 3p markers enabled us to define four nonoverlapping minimal deletion regions (OCLOHRs): (a) OCLOHR-1 mapped distal to D3S3591 at 3p25-26; (b) OCLOHR-2 mapped between D3S1317 and D3S1259 at 3p24-25; (c) OCLOHR-3 mapped between D3S1300 and D3S1284, an area that includes the FHIT locus at 3p14.2; and (d) OCLOHR-4 mapped between D3S1284 and D3S1274 at 3p12-13, a region known to contain overlapping homozygous deletions in lung and breast tumor cell lines. However, microsatellite markers from the chromosome 3p21.3 interval homozygously deleted in lung cancer cell lines did not identify a distinct OCLOHR. The frequency and extent of 3p LOH correlated with tumor stage such that LOH at two or more OCLOHRs was present in 53% (16 of 30) of stage III tumors but only 26% (5 of 19) of stage I/II tumors (P = 0.08). To determine the relationship between the OCLOHRs and the three candidate ovarian cancer suppression regions (OCSRs) identified previously by monochromosome transfer studies, we performed detailed genetic and physical mapping studies to define the extent of the three candidate OCSRs and to establish YAC contigs covering each region. OCSR-A at 3p25-26 and OCSR-B at 3p24 were shown to overlap with OCLOHR-1 and OCLOHR-2, respectively, providing further evidence for OCTSGs in these regions. We also show that OCSR-C overlaps with a locus at 3p21.3 previously implicated in lung and breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493522

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Authors:  Emily N Manderson; Anne-Marie Mes-Masson; Jaroslav Novak; Peter D Lee; Diane Provencher; Thomas J Hudson; Patricia N Tonin
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

2.  Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Authors:  Joseph Kwong; Ji-Young Lee; Kwong-Kwok Wong; Xiaofeng Zhou; David T W Wong; Kwok-Wai Lo; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

3.  Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family.

Authors:  Liang Liang; Mujun Zhao; Zhenhua Xu; Kazunari K Yokoyama; Tsaiping Li
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

4.  MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M.

Authors:  J Zhu; X Chen
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.

Authors:  Yoon-La Choi; So Young Kang; Young Kee Shin; Jong Sun Choi; Seok Hyung Kim; Sun-Joo Lee; Duk-Soo Bae; Geunghwan Ahn
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

Review 6.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

7.  Localization of the Fanconi anemia complementation group D gene to a 200-kb region on chromosome 3p25.3.

Authors:  J A Hejna; C D Timmers; C Reifsteck; D A Bruun; L W Lucas; P M Jakobs; S Toth-Fejel; N Unsworth; S L Clemens; D K Garcia; S L Naylor; M J Thayer; S B Olson; M Grompe; R E Moses
Journal:  Am J Hum Genet       Date:  2000-04-12       Impact factor: 11.025

8.  Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.

Authors:  Angelo Agathanggelou; Ivan Bièche; Jalal Ahmed-Choudhury; Barbara Nicke; Reinhard Dammann; Shairaz Baksh; Boning Gao; John D Minna; Julian Downward; Eamonn R Maher; Farida Latif
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.

Authors:  A Martinez; R A Walker; J A Shaw; S J Dearing; E R Maher; F Latif
Journal:  Mol Pathol       Date:  2001-10

10.  Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.

Authors:  W N Cooper; R E Dickinson; A Dallol; E V Grigorieva; T V Pavlova; L B Hesson; I Bieche; M Broggini; E R Maher; E R Zabarovsky; G J Clark; F Latif
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.